Article(id=1329527576860668349, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329527576395100605, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2024.11.001, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1727625600000, receivedDateStr=2024-09-30, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794913675751, onlineDateStr=2026-11-17, pubDate=1731168000000, pubDateStr=2024-11-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794913675751, onlineIssueDateStr=2026-11-17, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794913675751, creator=13701087609, updateTime=1794913675751, updator=13701087609, issue=Issue{id=1329527576395100605, tenantId=1146029695717560320, journalId=1319690329412173987, year='2024', volume='45', issue='11', pageStart='1105', pageEnd='1211', issueExtLink='null', onlineDate='null', pubDate='1731168000000', pubDateStr='2024-11-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794913675640, creator='13701087609', updateTime=1794962226160, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329731212412825960, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329527576395100605, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329731212412825961, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329527576395100605, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1105, endPage=1116, ext={EN=ArticleExt(id=1329527577078772158, articleId=1329527576860668349, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Expert consensus on the clinical application of anti-GD2 antibody naxitamab in the treatment of neuroblastoma (2024 Version), columnId=1326652874119033612, journalTitle=World Clinical Drug, columnName=Recommendation, runingTitle=null, highlight=null, articleAbstract=null, authors=Collaborative Group for Immunotherapy Clinical Practice in Neuroblastoma, authorsList=Collaborative Group for Immunotherapy Clinical Practice in Neuroblastoma, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329527577309458879, articleId=1329527576860668349, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=抗GD2单抗那西妥单抗治疗神经母细胞瘤临床应用专家共识(2024年版), columnId=1326652874295194382, journalTitle=世界临床药物, columnName=本期推荐, runingTitle=null, highlight=null, articleAbstract=null, authors=神经母细胞瘤免疫治疗临床应用协作组, authorsList=神经母细胞瘤免疫治疗临床应用协作组, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=pxpUUttdMDj1pXb4RWNcAw==, magXml=/unJLYA1YY1Fo2QivVXpBQ==, pdfUrl=null, pdf=ACcothD9+EchOyBXvfNEMQ==, pdfFileSize=2015392, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=XM31Ileur6/G4RsZEhOyEg==, mapNumber=null, fund=null)}, authors=[Author(id=1329532738228564979, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=2, ext={EN=AuthorExt(id=1329532738283090932, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, authorId=1329532738228564979, language=EN, stringName=Collaborative Group for Immunotherapy Clinical Practice in Neuroblastoma, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=null, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329532738350199797, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, authorId=1329532738228564979, language=CN, stringName=神经母细胞瘤免疫治疗临床应用协作组, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=null, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=null)], keywords=null, refs=[Reference(id=1329532738782213113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Su Y, Qin H, Chen C, et al. Treatment and outcomes of 1 041 pediatric patients with neuroblastoma who received multidisciplinary care in China[J]. Pediatr Investig, 2020, 4(3): 157-167., articleTitle=null, refAbstract=null), Reference(id=1329532738857710586, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Wu ZL, Schwartz E, Seeger R, et al. Expression of GD2 ganglioside by untreated primary human neuroblastomas[J]. Cancer Res, 1986, 46(1): 440-443., articleTitle=null, refAbstract=null), Reference(id=1329532738937402363, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Chan GC, Chan CM. Anti-GD2 directed immunotherapy for high-risk and metastatic neuroblastoma[J]. Biomolecules, 2022, 12(3): 358., articleTitle=null, refAbstract=null), Reference(id=1329532739000316924, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=苏雁, 马晓莉, 王焕民, 等. 单中心458例高危神经母细胞瘤患儿临床特征及预后分析[J]. 中华儿科杂志, 2020, 58(10): 796-801., articleTitle=null, refAbstract=null), Reference(id=1329532739063231485, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Sharp SE, Trout AT, Weiss BD, et al. MIBG in neuroblastoma diagnostic imaging and therapy[J]. Radiographics, 2016, 36(1): 258-278., articleTitle=null, refAbstract=null), Reference(id=1329532739138728958, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=曹雪涛. 医学免疫学[M]. 第7版. 北京: 人民卫生出版社, 2018: 11-12, 189-190., articleTitle=null, refAbstract=null), Reference(id=1329532739205837823, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Park JA, Cheung NV. Targets and antibody formats for immunotherapy of neuroblastoma[J]. J Clin Oncol, 2020, 38(16): 1836-1848., articleTitle=null, refAbstract=null), Reference(id=1329532739272946688, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=中国抗癌协会小儿肿瘤专业委员会, 中华医学会小儿外科学分会肿瘤学组. 儿童神经母细胞瘤诊疗专家共识CCCG-NB-2021方案[J]. 中华小儿外科杂志, 2022, 43(7): 588-598., articleTitle=null, refAbstract=null), Reference(id=1329532739335860224, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=PDQ Pediatric Treatment Editorial Board. Neuroblastoma treatment (PDQ®): health professional version[EB/OL]. National Cancer Institute (US), (2022-06-09) [2024-08-01]. https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq., articleTitle=null, refAbstract=null), Reference(id=1329532739415552001, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma[J]. Expert Rev Anticancer Ther, 2017, 17(10): 889-904., articleTitle=null, refAbstract=null), Reference(id=1329532739478466562, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Voeller J, Sondel P. Advances in anti-GD2 immunotherapy for treatment of high-risk neuroblastoma[J]. J Pediatr Hematol Oncol, 2019, 41(3): 163-169., articleTitle=null, refAbstract=null), Reference(id=1329532739549769731, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Neuroblastoma, version 1. 2024[EB/OL]. (2024-02-07) [2024-08-01]. https://www.nccn.org/guidelines., articleTitle=null, refAbstract=null), Reference(id=1329532741189742597, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Morgenstern D, Mora J, Chan G, et al. 74P pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)[J]. Ann Oncol, 2020, 31: S1448., articleTitle=null, refAbstract=null), Reference(id=1329532741269434374, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Varo A, Castaneda A, Chamorro S, et al. Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab[J]. Front Oncol, 2023, 13: 1164949., articleTitle=null, refAbstract=null), Reference(id=1329532741353320455, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Mora J, Chan G, Morgenstern D, et al. Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: management of adverse events[J]. Cancer Rep (Hoboken), 2023, 6(1): e1627., articleTitle=null, refAbstract=null), Reference(id=1329532741433012232, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Cheung N, Lazarus H, Miraldi F, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase Ⅰ study in patients with neuroblastoma and malignant melanoma[J]. J Clin Oncol, 1987, 5(9): 1430-1440., articleTitle=null, refAbstract=null), Reference(id=1329532741525286921, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Cheung N, Guo H, Hu J, et al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo[J]. Oncoimmunology, 2012, 1(4): 477-486., articleTitle=null, refAbstract=null), Reference(id=1329532741596590090, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Lisby S, Liebenberg N, Bukrinski J, et al. Naxitamab, an antibody with distinct complementary determining regions and high binding affinity to disialoganglioside GD2[J]. Pediatr Blood Cancer, 2020, 67(Suppl 4): e28742., articleTitle=null, refAbstract=null), Reference(id=1329532741680476171, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=赛生药业. 那西妥单抗注射液说明书[EB/OL]. (2022-11-30) [2024-08-01]. www. sciclone. com., articleTitle=null, refAbstract=null), Reference(id=1329532741747585036, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Mody R, Yu A, Naranjo A, et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the children's oncology group[J]. J Clin Oncol, 2020, 38(19): 2160-2169., articleTitle=null, refAbstract=null), Reference(id=1329532741810499597, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Armitage J. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor[J]. Blood, 1998, 92(12): 4491-4508., articleTitle=null, refAbstract=null), Reference(id=1329532741873414158, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Cheung I, Hsu K, Cheung N. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor[J]. J Clin Oncol, 2012, 30(4): 426-432., articleTitle=null, refAbstract=null), Reference(id=1329532741944717327, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Yu A, Gilman A, Ozkaynak F, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma[J]. N Engl J Med, 2010, 363(14): 1324-1334., articleTitle=null, refAbstract=null), Reference(id=1329532742016020496, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Kushner B, Cheung I, Modak S, et al. Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma: a phase 1 clinical trial[J]. J Am Med Assoc Oncol, 2018, 4(12): 1729-1735., articleTitle=null, refAbstract=null), Reference(id=1329532742087323665, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Markham A. Naxitamab: first approval[J]. Drugs, 2021, 81(2): 291-296., articleTitle=null, refAbstract=null), Reference(id=1329532742175404050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Kushner B, Chan G, Morgenstern D, et al. 109P impact of anti-drug antibody (ADA) on naxitamab efficacy and safety[J]. Immunooncol Technol, 2022, 16: 24-25., articleTitle=null, refAbstract=null), Reference(id=1329532742255095827, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=National Library of Medicine. Study of chemoimmunotherapy for high-risk neuroblastoma[DB/OL]. (2024-07-03) [2024-08-01]. http://clinicaltrials.gov/study/NCT03189706., articleTitle=null, refAbstract=null), Reference(id=1329532742318010388, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=National Library of Medicine. Naxitamab for high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow[DB/OL]. (2024-09-19) [2024-09-20]. http://clinicaltrials.gov/study/NCT03363373., articleTitle=null, refAbstract=null), Reference(id=1329532742376730645, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Mora J, Bear, M, Chan G, et al. Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: outcomes from the first prespecified analyses of the pivotal 201 trial[J]. Ann Oncol, 2022, 33(7): S956., articleTitle=null, refAbstract=null), Reference(id=1329532742452228118, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Mora J, Chan G, Morgenstern D, et al. Reduction in curie score in neuroblastoma patients treated with naxitamab[R]. Chicago: American Society of Clinical Oncology (ASCO) Annual Meeting, 2023., articleTitle=null, refAbstract=null), Reference(id=1329532742515142679, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Kushner B, Modak S, Basu E, et al. High-dose naxitamab (humanized-3F8) PLUS stepped-up dosing of granulocyte-macrophage colony-stimulating factor (GM-CSF) for resistant osteomedullary neuroblastoma: major responses and outpatient treatment in a phase Ⅱ trial[J]. Pediatr Blood Cancer, 2020, 67(Suppl 4): e28742., articleTitle=null, refAbstract=null), Reference(id=1329532742586445848, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Modak S, Kushner B, Mauguen A, et al. Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: results of "HITS" phase Ⅱ study[J]. J Clin Oncol, 2022, 40(Suppl 16): 10028., articleTitle=null, refAbstract=null), Reference(id=1329532742666137625, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Munoz J, Larrosa C, Chamorro S, et al. Early salvage chemo-immunotherapy with irinotecan, temozolomide and naxitamab plus GM-CSF (HITS) for patients with primary refractory high-risk neuroblastoma provide the best chance for long-term outcomes[J]. Cancers, 2023, 15(19): 4837., articleTitle=null, refAbstract=null), Reference(id=1329532742770995226, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Mora J, Castaneda A, Gorostegui M, et al. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission[J]. Pediatr Blood Cancer, 2021, 68(10): e29121., articleTitle=null, refAbstract=null), Reference(id=1329532742842298395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Mora J, Castaneda A, Gorostegui M, et al. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in first complete remission under compassionate use-updated outcome report[J]. Cancers (Basel), 2023, 15(9): 2535., articleTitle=null, refAbstract=null), Reference(id=1329532742909407260, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Kushner B, Modak S, Mauguen A, et al. High-dose naxitamab PLUS stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in first complete remission: a phase Ⅱtrial[R]. Amsterdam: NR2023 – Poster Presentations and Rapid Fire Sessions, 2023., articleTitle=null, refAbstract=null), Reference(id=1329532742972321821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Larrosa C, Simao M, Munoz J, et al. Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma[R]. Chicago: American Society of Clinical Oncology (ASCO) Annual Meeting, 2024., articleTitle=null, refAbstract=null), Reference(id=1329532743031042078, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Park JR, Bagatell R, Cohn SL, et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the national cancer institute clinical trials planning meeting[J]. J Clin Oncol, 2017, 35(22): 2580-2587., articleTitle=null, refAbstract=null), Reference(id=1329532743106539551, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=胡闻竹, 覃春霞, 兰晓莉. 核素显像在神经母细胞瘤中的临床应用及进展[J]. 中华核医学与分子影像杂志, 2024, 44(1): 55-60., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329532738484417526, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, awardId=22023YFC2706301; 2022YFC2705002; 2022YFC2705003, language=CN, fundingSource=国家重点研发计划(22023YFC2706301; 2022YFC2705002; 2022YFC2705003), fundOrder=null, country=null), Fund(id=1329532738551526391, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, awardId=2023ZDFC0103, language=CN, fundingSource=上海市卫生健康系统重点扶持学科项目(2023ZDFC0103), fundOrder=null, country=null), Fund(id=1329532738631218168, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, awardId=ZSBK0070, language=CN, fundingSource=唐仲英基金会(ZSBK0070), fundOrder=null, country=null)], companyList=null, figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.11.001, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.11.001, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2024.11.001, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2024.11.001, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1731168000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
抗GD2单抗那西妥单抗治疗神经母细胞瘤临床应用专家共识(2024年版)
神经母细胞瘤免疫治疗临床应用协作组
世界临床药物 | 本期推荐 2024,45(11): 1105-1116
收起
收藏切换
世界临床药物 |本期推荐 2024 , 45 (11) : 1105 -1116
抗GD2单抗那西妥单抗治疗神经母细胞瘤临床应用专家共识(2024年版)
全屏
[Author(id=1329532738228564979, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=2, ext={EN=AuthorExt(id=1329532738283090932, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, authorId=1329532738228564979, language=EN, stringName=Collaborative Group for Immunotherapy Clinical Practice in Neuroblastoma, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=null, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329532738350199797, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527576860668349, authorId=1329532738228564979, language=CN, stringName=神经母细胞瘤免疫治疗临床应用协作组, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=null, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=null)]
神经母细胞瘤免疫治疗临床应用协作组
作者信息
Expert consensus on the clinical application of anti-GD2 antibody naxitamab in the treatment of neuroblastoma (2024 Version)
Collaborative Group for Immunotherapy Clinical Practice in Neuroblastoma
Affiliations
出版时间: 2024-11-10 doi: 10.13683/j.wph.2024.11.001
文章导航
收藏切换
神经母细胞瘤免疫治疗临床应用协作组. 抗GD2单抗那西妥单抗治疗神经母细胞瘤临床应用专家共识(2024年版). 世界临床药物, 2024 , 45 (11) : 1105 -1116 . DOI: 10.13683/j.wph.2024.11.001
Collaborative Group for Immunotherapy Clinical Practice in Neuroblastoma. Expert consensus on the clinical application of anti-GD2 antibody naxitamab in the treatment of neuroblastoma (2024 Version)[J]. World Clinical Drug, 2024 , 45 (11) : 1105 -1116 . DOI: 10.13683/j.wph.2024.11.001
  • 国家重点研发计划(22023YFC2706301; 2022YFC2705002; 2022YFC2705003)
  • 上海市卫生健康系统重点扶持学科项目(2023ZDFC0103)
  • 唐仲英基金会(ZSBK0070)
参考文献 引证文献
排序方式:
[1]
Su Y, Qin H, Chen C, et al. Treatment and outcomes of 1 041 pediatric patients with neuroblastoma who received multidisciplinary care in China[J]. Pediatr Investig, 2020, 4(3): 157-167.
[2]
Wu ZL, Schwartz E, Seeger R, et al. Expression of GD2 ganglioside by untreated primary human neuroblastomas[J]. Cancer Res, 1986, 46(1): 440-443.
[3]
Chan GC, Chan CM. Anti-GD2 directed immunotherapy for high-risk and metastatic neuroblastoma[J]. Biomolecules, 2022, 12(3): 358.
[4]
苏雁, 马晓莉, 王焕民, 等. 单中心458例高危神经母细胞瘤患儿临床特征及预后分析[J]. 中华儿科杂志, 2020, 58(10): 796-801.
[5]
Sharp SE, Trout AT, Weiss BD, et al. MIBG in neuroblastoma diagnostic imaging and therapy[J]. Radiographics, 2016, 36(1): 258-278.
[6]
曹雪涛. 医学免疫学[M]. 第7版. 北京: 人民卫生出版社, 2018: 11-12, 189-190.
[7]
Park JA, Cheung NV. Targets and antibody formats for immunotherapy of neuroblastoma[J]. J Clin Oncol, 2020, 38(16): 1836-1848.
[8]
中国抗癌协会小儿肿瘤专业委员会, 中华医学会小儿外科学分会肿瘤学组. 儿童神经母细胞瘤诊疗专家共识CCCG-NB-2021方案[J]. 中华小儿外科杂志, 2022, 43(7): 588-598.
[9]
PDQ Pediatric Treatment Editorial Board. Neuroblastoma treatment (PDQ®): health professional version[EB/OL]. National Cancer Institute (US), (2022-06-09) [2024-08-01]. https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq.
[10]
Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma[J]. Expert Rev Anticancer Ther, 2017, 17(10): 889-904.
[11]
Voeller J, Sondel P. Advances in anti-GD2 immunotherapy for treatment of high-risk neuroblastoma[J]. J Pediatr Hematol Oncol, 2019, 41(3): 163-169.
[12]
NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Neuroblastoma, version 1. 2024[EB/OL]. (2024-02-07) [2024-08-01]. https://www.nccn.org/guidelines.
[13]
Morgenstern D, Mora J, Chan G, et al. 74P pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)[J]. Ann Oncol, 2020, 31: S1448.
[14]
Varo A, Castaneda A, Chamorro S, et al. Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab[J]. Front Oncol, 2023, 13: 1164949.
[15]
Mora J, Chan G, Morgenstern D, et al. Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: management of adverse events[J]. Cancer Rep (Hoboken), 2023, 6(1): e1627.
[16]
Cheung N, Lazarus H, Miraldi F, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase Ⅰ study in patients with neuroblastoma and malignant melanoma[J]. J Clin Oncol, 1987, 5(9): 1430-1440.
[17]
Cheung N, Guo H, Hu J, et al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo[J]. Oncoimmunology, 2012, 1(4): 477-486.
[18]
Lisby S, Liebenberg N, Bukrinski J, et al. Naxitamab, an antibody with distinct complementary determining regions and high binding affinity to disialoganglioside GD2[J]. Pediatr Blood Cancer, 2020, 67(Suppl 4): e28742.
[19]
赛生药业. 那西妥单抗注射液说明书[EB/OL]. (2022-11-30) [2024-08-01]. www. sciclone. com.
[20]
Mody R, Yu A, Naranjo A, et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the children's oncology group[J]. J Clin Oncol, 2020, 38(19): 2160-2169.
[21]
Armitage J. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor[J]. Blood, 1998, 92(12): 4491-4508.
[22]
Cheung I, Hsu K, Cheung N. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor[J]. J Clin Oncol, 2012, 30(4): 426-432.
[23]
Yu A, Gilman A, Ozkaynak F, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma[J]. N Engl J Med, 2010, 363(14): 1324-1334.
[24]
Kushner B, Cheung I, Modak S, et al. Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma: a phase 1 clinical trial[J]. J Am Med Assoc Oncol, 2018, 4(12): 1729-1735.
[25]
Markham A. Naxitamab: first approval[J]. Drugs, 2021, 81(2): 291-296.
[26]
Kushner B, Chan G, Morgenstern D, et al. 109P impact of anti-drug antibody (ADA) on naxitamab efficacy and safety[J]. Immunooncol Technol, 2022, 16: 24-25.
[27]
National Library of Medicine. Study of chemoimmunotherapy for high-risk neuroblastoma[DB/OL]. (2024-07-03) [2024-08-01]. http://clinicaltrials.gov/study/NCT03189706.
[28]
National Library of Medicine. Naxitamab for high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow[DB/OL]. (2024-09-19) [2024-09-20]. http://clinicaltrials.gov/study/NCT03363373.
[29]
Mora J, Bear, M, Chan G, et al. Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: outcomes from the first prespecified analyses of the pivotal 201 trial[J]. Ann Oncol, 2022, 33(7): S956.
[30]
Mora J, Chan G, Morgenstern D, et al. Reduction in curie score in neuroblastoma patients treated with naxitamab[R]. Chicago: American Society of Clinical Oncology (ASCO) Annual Meeting, 2023.
[31]
Kushner B, Modak S, Basu E, et al. High-dose naxitamab (humanized-3F8) PLUS stepped-up dosing of granulocyte-macrophage colony-stimulating factor (GM-CSF) for resistant osteomedullary neuroblastoma: major responses and outpatient treatment in a phase Ⅱ trial[J]. Pediatr Blood Cancer, 2020, 67(Suppl 4): e28742.
[32]
Modak S, Kushner B, Mauguen A, et al. Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: results of "HITS" phase Ⅱ study[J]. J Clin Oncol, 2022, 40(Suppl 16): 10028.
[33]
Munoz J, Larrosa C, Chamorro S, et al. Early salvage chemo-immunotherapy with irinotecan, temozolomide and naxitamab plus GM-CSF (HITS) for patients with primary refractory high-risk neuroblastoma provide the best chance for long-term outcomes[J]. Cancers, 2023, 15(19): 4837.
[34]
Mora J, Castaneda A, Gorostegui M, et al. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission[J]. Pediatr Blood Cancer, 2021, 68(10): e29121.
[35]
Mora J, Castaneda A, Gorostegui M, et al. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in first complete remission under compassionate use-updated outcome report[J]. Cancers (Basel), 2023, 15(9): 2535.
[36]
Kushner B, Modak S, Mauguen A, et al. High-dose naxitamab PLUS stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in first complete remission: a phase Ⅱtrial[R]. Amsterdam: NR2023 – Poster Presentations and Rapid Fire Sessions, 2023.
[37]
Larrosa C, Simao M, Munoz J, et al. Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma[R]. Chicago: American Society of Clinical Oncology (ASCO) Annual Meeting, 2024.
[38]
Park JR, Bagatell R, Cohn SL, et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the national cancer institute clinical trials planning meeting[J]. J Clin Oncol, 2017, 35(22): 2580-2587.
[39]
胡闻竹, 覃春霞, 兰晓莉. 核素显像在神经母细胞瘤中的临床应用及进展[J]. 中华核医学与分子影像杂志, 2024, 44(1): 55-60.
2024年第45卷第11期
24
6
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2024.11.001
  • 接收时间:2024-09-30
  • 首发时间:2026-11-17
  • 出版时间:2024-11-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-09-30
基金
国家重点研发计划(22023YFC2706301; 2022YFC2705002; 2022YFC2705003)
上海市卫生健康系统重点扶持学科项目(2023ZDFC0103)
唐仲英基金会(ZSBK0070)
作者信息
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.11.001
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏